Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03551600 · ClinicalTrials.gov registry record

Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus

A clinical trial of Congenital Heart Disease and Infant, Premature, sponsored by University of Utah.

Completed
Registry status
64
Enrollment target
3
Study locations

NCT03551600: Completed study of Congenital Heart Disease and Infant, Premature, sponsored by University of Utah.

NCT03551600 is a study of Congenital Heart Disease and Infant, Premature that has completed, run by University of Utah. The registered enrollment target is 64 participants, below the 473-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03551600, a study of Congenital Heart Disease and Infant, Premature, has completed, sponsored by University of Utah.

COMPLETED
Registry status
64 participants
Enrollment target
3
Study locations

Study Summary

Patent ductus arteriosus (PDA) is a common problem in the neonatal intensive care unit and can be secondary to prematurity or congenital heart disease (CHD). PDA is the most common cardiovascular abnormality in preterm infants, and is seen in 55% of infants born at 28 weeks, and 1000 grams or less. In addition to producing heart failure and prolonged respiratory distress or ventilator dependence, PDA has been implicated in development of broncho-pulmonary dysplasia, interventricular hemorrhage, cerebral ischemia, and necrotizing enterocolitis (NEC). In an Israeli population study 5.6% of all very low birth weight infants (VLBW) were diagnosed with NEC, and 9.4% of VLBW infants with PDA were found to have NEC. In a retrospective analysis of neonates with CHD exposed to Prostaglandin E found that the odds of developing NEC increased in infants with single ventricle physiology, especially hypoplastic left heart syndrome. The proposed pathophysiological explanation of NEC and PDA is a result of "diastolic steal" where blood flows in reverse from the mesenteric arteries back into the aorta leading to compromised diastolic blood flow and intestinal hypo-perfusion. Prior studies have demonstrated that infants with a hemodynamically significant PDA have decreased diastolic flow velocity of the mesenteric and renal arteries when measured by Doppler ultrasound, and an attenuated intestinal blood flow response to feedings in the post prandial period compared to infants without PDA. Near Infrared Spectroscopy (NIRS) has also been used to assess regional oxygen saturations (rSO2) in tissues such as the brain, kidney and mesentery in premature infants with PDA. These studies demonstrated lower baseline oxygenation of these tissues in infants with hemodynamically significant PDA. These prior NIRS studies evaluated babies with a median gestational age at the time of study of 10 days or less. It is unknown if this alteration in saturations will persist in extubated neonates with PDA

Primary Outcome

Compare the baseline renal and splanchnic rSO2 measurements between preterm, late preterm, and term infants with a patent ductus arteriosus to those infants without a patent ductus arteriosus

Interventions

  • PROCEDURE Near-infrared spectroscopy (NIRS)

Study Locations (3)

Utah

  • Intermountain Medical Center - Murray
  • University of Utah Health - Salt Lake City
  • Primary Children's Hospital - Salt Lake City

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2015-10
Est. Completion 2022-06-30
University of Utah

818 total trials

What the finished NCT03551600 record still lists

NCT03551600 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 473-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (86% lower).

The record links to 4 conditions, with Congenital Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which Near-infrared spectroscopy (NIRS) is the first listed.

NCT03551600 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT03551600 about?

NCT03551600 is a clinical study titled "Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus". Patent ductus arteriosus (PDA) is a common problem in the neonatal intensive care unit and can be secondary to prematurity or congenital heart disease (CHD). PDA is the most common cardiovascular abnormality in preterm infants, and is seen in 55% of infants born at 28 weeks, and 1000 grams or less. ...

What is the current status of trial NCT03551600?

This trial is currently completed. The enrollment target is 64 participants. The study started on 2015-10. Estimated completion is 2022-06-30.

What conditions does trial NCT03551600 study?

This clinical trial studies the following conditions: Congenital Heart Disease, Infant, Premature, Necrotizing Enterocolitis, Patent Ductus Arteriosus.

What interventions are being tested in trial NCT03551600?

The interventions under investigation include: Near-infrared spectroscopy (NIRS) (PROCEDURE).

Who is sponsoring clinical trial NCT03551600?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03551600 being conducted?

This trial has 3 study locations across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Congenital Heart Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03551600's enrollment target sits among peer trials

64 36th of 63 higher than 28 of 63 other Congenital Heart Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Congenital Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03551600, the US trial registry maintained by the National Library of Medicine. NCT03551600 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.